BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 17013569)

  • 1. Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine.
    Fleischer G; Dörr W
    Strahlenther Onkol; 2006 Oct; 182(10):567-75. PubMed ID: 17013569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa.
    Gehrisch A; Dörr W
    Strahlenther Onkol; 2007 Jan; 183(1):36-42. PubMed ID: 17225944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice.
    Dörr W; Bässler S; Reichel S; Spekl K
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):881-7. PubMed ID: 15936573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation.
    Dörr W; Reichel S; Spekl K
    Radiother Oncol; 2005 Apr; 75(1):99-105. PubMed ID: 15878107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF.
    Dörr W; Heider K; Spekl K
    Int J Radiat Biol; 2005 Aug; 81(8):557-65. PubMed ID: 16298937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dexpanthenol with or without Aloe vera extract on radiation-induced oral mucositis: preclinical studies.
    Dörr W; Schlichting S; Bray MA; Flockhart IR; Hopewell JW
    Int J Radiat Biol; 2005 Mar; 81(3):243-50. PubMed ID: 16019933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraoral manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis.
    Epperly MW; Carpenter M; Agarwal A; Mitra P; Nie S; Greenberger JS
    In Vivo; 2004; 18(4):401-10. PubMed ID: 15369176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies.
    Haagen J; Krohn H; Röllig S; Schmidt M; Wolfram K; Dörr W
    Radiother Oncol; 2009 Sep; 92(3):472-6. PubMed ID: 19576646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity.
    Vujaskovic Z; Feng QF; Rabbani ZN; Samulski TV; Anscher MS; Brizel DM
    Exp Lung Res; 2002; 28(7):577-90. PubMed ID: 12396250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets.
    Srinivasan V; Pendergrass JA; Kumar KS; Landauer MR; Seed TM
    Int J Radiat Biol; 2002 Jun; 78(6):535-43. PubMed ID: 12065057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of insulin-like growth factor-1 (IGF-1) and amifostine in spinal cord reirradiation.
    Nieder C; Price RE; Rivera B; Andratschke N; Ang KK
    Strahlenther Onkol; 2005 Nov; 181(11):691-5. PubMed ID: 16254703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route.
    Koukourakis MI; Simopoulos C; Minopoulos G; Patlakas G; Polychronidis A; Limberis V; Romanides K; Pitiacoudis M; Manolas C
    Clin Cancer Res; 2003 Aug; 9(9):3288-93. PubMed ID: 12960114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recombinant human keratinocyte growth factor (rHuKGF, Palifermin) on radiation-induced mouse urinary bladder dysfunction.
    Jaal J; Dörr W
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):528-33. PubMed ID: 17869665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of radiation-induced oral mucositis (mouse) by selective inhibition of β1 integrin.
    Albert M; Schmidt M; Cordes N; Dörr W
    Radiother Oncol; 2012 Aug; 104(2):230-4. PubMed ID: 22841020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection.
    Mangoni M; Yue X; Morin C; Violot D; Frascogna V; Tao Y; Opolon P; Castaing M; Auperin A; Biti G; Barritault D; Vozenin-Brotons MC; Deutsch E; Bourhis J
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1242-50. PubMed ID: 19545790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
    Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.